CTOs on the Move

Kedrion

www.kedrion.com

 
Kedrion Biopharma develops and produces plasma-derived therapies, making them available to meet patients` needs the world over. We collect and fractionate blood plasma for the development, production and distribution of plasma derivatives used in the treatment of patients suffering from rare and chronic conditions such as hemophilia and immune system deficiencies. A corporation is not a person, but a corporation is run by people and it affects people. And Kedrion`s business is people. The very nature of our enterprise is to help people live more full and healthy lives. This commitment extends to how we conduct our business, that is, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.kedrion.com
  • 400 Kelby St Fl 11
    Fort Lee, NJ USA 07024
  • Phone: 201.242.8900

Executives

Name Title Contact Details

Similar Companies

Satellite Healthcare

Making Life Better for Those Living with Kidney Disease. For nearly 40 years, our mission has remained unchanged. From the patient chair side to the boardroom, this powerful yet practical principle guides our daily clinical work as well as our leadership decisions.

Monitor Medical Inc

Monitor Medical Inc is a Stafford, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kolltan

Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.

Nutex Health

The Future of Healthcare Nutex Health Inc. is a technology-enabled health management company with two divisions: Business Development Marketing Operations Coordination Legal Human Resources Accounting Billing & Collections Nutex Health Inc. is a techno...

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.